Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Lymphoma, Large B-Cell, Diffuse 9Hodgkin Disease 7Sarcoma 6Lymphoma 6Testicular Neoplasms 5Testicular Germ Cell Tumor 5Ovarian Neoplasms 5Osteosarcoma 5Lymphoma, Follicular 5Lymphoma, Non-Hodgkin 4Lymphoma, Mantle-Cell 4Lymphoma, Large-Cell, Anaplastic 4Burkitt Lymphoma 4Recurrence 3Lymphoma, Large-Cell, Immunoblastic 3Immunoblastic Lymphadenopathy 3Central Nervous System Neoplasms 3Waldenstrom Macroglobulinemia 2Teratoma 2Solitary Fibrous Tumors 2Small Cell Lung Carcinoma 2Sarcoma, Clear Cell 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Neoplasms 2Lymphoma, Extranodal NK-T-Cell 2Lymphoma, B-Cell, Marginal Zone 2Leukemia, Lymphocytic, Chronic, B-Cell 2Hemangiosarcoma 2Hemangioendothelioma, Epithelioid 2Dendritic Cell Sarcoma, Interdigitating 2

Interventions

neratinib 1fludarabine 1famitinib 1encorafenib 1camrelizumab 1Valproic Acid 1Taxes 1TPI-287 1Sodium Selenite 1Nivolumab 1Ifosfamide 1Gemcitabine 1Cyclophosphamide 1Clinical Trials, Phase II as Topic 1Clinical Trials, Phase I as Topic 1Cetuximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Disease Progression × Ifosfamide × Clear all
NCT04044378 2020-05-19

Famitinib Plus Camrelizumab & Famitinib Alone & Famitinib Plus Ifosfamide in Advanced Osteosarcoma

Peking University People's Hospital

Phase 1/2 Withdrawn

Neoplasms, Disease Progression

Data powered by HemOnc (CC BY 4.0) Colophon âš¡